METRO launches self-driving shuttle, Data Gumbo hires new exec, and more Houston innovation news

Short stories

METRO launches a driver-less route, Houston biotech company raises millions, and more quick innovation news. Courtesy of METRO

So much Houston innovation news — so little time. In order to help keep in touch with all the news happening among startups and technology in Houston, we're hitting the highlights in this innovation news roundup.

If you know of innovation-focused news happening, email me at natalie@innovationmap.com with the details and subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.


METRO launches a self-driving shuttle on Texas Southern University's campus

Courtesy of Metro

The first autonomous shuttle in Houston recently had its maiden voyage on Texas Southern University's campus. The route is a one-mile stretch that is called the "Tiger Walk.' The EasyMile shuttle can transport 12 passengers and is operated by First Transit. The project is a pilot program for METRO to see if it has successful applications in other public transportation efforts.

"When passengers board this all electric vehicle they will be riding into the future and experiencing a mode of transportation that in just a few years may become commonplace," says METRO Chair Carrin Patman in a release.

The first phase of the pilot kicked off June 5, as reported in a previous InnovationMap article.

After being deemed a hot tech company by Crunchbase, Data Gumbo grows its C-suite

Courtesy of Data Gumbo

In June, Data Gumbo was named among Crunchbase's top 50 hottest tech companies. The list looked for growing tech startups that have raised between $5 million and $20 million, with a recent round closing in the past six months. The Houston-based company closed its most recent round of $6 million in the spring.

Following the round completion, Data Gumbo's CEO, Andrew Bruce, noted the funds were intended to further develop the company's technology and grow the team. As of last week, Bruce made good on the promise and announced the company's new chief commercial officer, Sergio A. Tuberquia.

"As our new capital is being used to expand our commercial blockchain network, we are also expanding our internal teams to support our rapid global growth," says Bruce in a news release. "With Sergio joining to lead revenue efforts, this will further our company's mission to help oil and gas companies — and ultimately all industries -—realize greater efficiencies and cost savings in the supply chain. Sergio's mix of startup technology and oil and gas industry experience will greatly benefit Data Gumbo and its customers as the industry moves into digital oilfield solutions like blockchain."

Biotech company extends its Series D round to $43 million

Getty Images

Following a $20 million commitment from Sanford Health, Houston-based InGeneron Inc. has extended its Series D round to $43 million. The funds will go toward further developing the company's regenerative medicine and cell therapy. InGeneron currently has a clinical study for rotator cuff recovery.

The investment by South Dakota-based Sanford Health was announced in March, and last month, InGeneron made the call to expand the series.

"Sanford Health's continued support helps advance InGeneron's regenerative cell therapy into the expansive pivotal trial phase, a significant step toward bringing our therapy into the clinic," says Angelo Moesslang, CEO of InGeneron, in a release. "This is an exciting time for the company, as one of the largest health systems in the United States further affirms the potential of adipose-derived regenerative cell therapy, while we diligently work to make it available to patients."

Rice Business Plan winner to ring the Nasdaq bell

Courtesy of Rice University

The company that won the top prize at the Rice Business Plan Competition and walked away with almost $700,000 is claiming another one of its prizes. Vita Inclinata Technologies will ring the opening bell at Nasdaq on July 3.

The company, which created a technology to advance helicopter safety, will be represented by its CEO, Caleb Carr, and Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship, and Will Roper, the U.S. Air Force's assistant secretary for acquisition, will also attend. The livestream footage is available online, beginning at 8:30 am central.

Mercury Fund raising money

Texas Money

Getty Images

Crunchbase broke the news that Houston-based Mercury Fund has secured $82 million of its fourth fund, Mercury Fund Ventures IV, that will total $125 million, per a regulatory filing that PE Hub reported on. Mercury Fund refused to comment on the ongoing raise, but intends to release more information following the close, a representative confirmed to InnovationMap.

According to Crunchbase's proprietary data, it's the largest fund to date for the firm. The most recent fund closed in 2014 at $105 million. Mercury Fund specializes in SaaS, cloud, and data science technology, according to its website.

Rice University and Baylor College of Medicine researcher recognized

Courtesy of Rice University

Olga Dudchenko, a genomics researcher at Rice University and Baylor College of Medicine, been named to MIT Technology Review magazine's 2019 list of 35 Innovators Under 35.

Dudchenko, who is completing her postdoctoral fellowship at Rice's Center for Theoretical Biological Physics, has developed a method to sequence and assemble the genome of any organism for less than $1,000. Her process is comparable the that of the Human Genome Project, which cost $3 billion.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings